I løpet av de siste par årene har man innen medisin sett en stor og bred bølge av nye behandlinger som målretter sykdom gjennom det menneskelige genomet, også kjent som det menneskelige DNAet. Arctic Aurora LifeScience-teamet har skrevet en introduksjon til området som gir investorer et innblikk i genterapi og fremtiden for genteknologi i årene som kommer. Dokumentet er på engelsk og har en lesetid på ca 15 minutter.
Since the genome or the full human DNA sequence was mapped during the nineties and early new millennia, researchers could identify genes that caused disease when lacking due to mutations or gone into overdrive and too much of a protein was being produced. However, it took scientists and drug developers nearly two decades before the technology was considered good enough in order to safely and effectively deliver genetic material directly into humans. But as the floodgates appear to have opened, we have now witnessed the first approved genomic drugs and many more are in late-stage development and therefore are one of the main focuses of Arctic Aurora LifeScience fund.
Read more in the paper written by the Arctic Aurora LifeScience
- Arctic Aurora LifeScience - Introduction to gene therapy (Reading time: 15 minutes)
Arctic Aurora LifeScience is an equity fund investing in global biotechnology and pharmaceutical companies. The fund is run by former portfolio manager in the Swedish Governmental Pension Fund AP3, Ulrica Bjerke, as well as Dr. Torbjørn Bjerke, both with 20 years of experience from the market. Arctic Aurora LifeScience was launched in May 2016 with both hedged and un-hedged share classes.
Past performance in Arctic Aurora LifeScience is no guarantee for future returns. Future returns depend on the market, fund manager skill, fund risk level, costs, among others. Performance in the fund may at times be negative and may for this fund vary considerably within periods.